Lemtrada Patients Report Positive Experiences From Taking The Anti-MS Drug
A person has to know what multiple sclerosis patients go through to understand why they would risk their lives by taking the drug Lemtrada
Tuesday, February 4, 2020 - Lemtrada, manufactured by Sanofi Inc., is a disease-modifying therapy administered by intravenous infusion to treat Relapsing-Remitting Multiple Sclerosis and was approved by the FDA in 2014. Lemtrada is highly restricted by the FDA and Europe's Medical Agency because it can cause arterial dissection, leading to a stroke within 24-72 hours after the intravenous infusions begin. The drug can only be prescribed as a last resort after two or more other anti-RRMS drugs have been tried and failed and the drug can only be administered to a patient under the supervision of emergency room staff in case the patient has a stroke, heart attack, or other serious response. Multiple Sclerosis.net interviewed a Lemtrada patient and asked questions about a woman's experience on the drug. Lemtrada attorneys are helping families and individuals that are suffering from MS and were exposed to arterial dissection and stroke since 2014, with no warnings and offer a free consultation before filing a lawsuit claim.
The woman who remained anonymous was diagnosed with relapse remitting multiple sclerosis (RRMS) after suffering for years with Lupus. The patient's condition had deteriorated to critical and she suffered from "having to use a wheelchair, slurred speech, loss of bladder and bowel control, cognitive disorder, severe pain, and muscle spasms." The woman's disease had entered the primary progressive stage and her doctor told her that there was no drug to treat her. The patient experienced lesions on her neck and at the base of her brain. A British doctor reviewing her case suggested that she try Lemtrada, a then-new and unproven, yet promising anti-RRMS drug that was having success in Europe.
The woman's Lemtrada treatment started in 2006 and lasted 5 hours per day over three days. Lemtrada treatments are administered only once per year for three years with an option for years four and five. The woman dealt with the general side effects of the drug but according to her were worth it because of the "amazing" results she experienced. "After the third dose, I was out of the wheelchair and a lot of my symptoms had reversed themselves. Even my lesions had disappeared on my MRI's. It was my Miracle Drug," the patient explained. The patients walked up to 4 miles per day without assistance and contemplated going back to work. After the third year, her symptoms began to return, however, and she opted to restart treatment for years 4 and 5.
Today, Lemtrada patients' primary fear is having a stroke within 24 - 72 hours of their first treatment. According to Lemtrada.com, Lemtrada's most dangerous symptoms are "Stroke and tears in your arteries that supply blood to your brain (carotid and vertebral arteries): Some people have had serious and sometimes deadly strokes and tears in their carotid or vertebral arteries within 3 days of receiving LEMTRADA. "
The following are signs that you could be about to have a stroke and to immediately seek medical help: "drooping of parts of your face, weakness on one side, sudden severe headache, difficulty with speech, and neck pain."
More Recent Lemtrada Stroke Lawsuit News:
- Lemrtrada Risks Were Worth It For One Recent Patient | 4/14/2021
- The Shocking Types of Deaths Caused By Lemtrada | 4/9/2021
- RRMS Has Different Stages With Different Symptoms | 4/5/2021
- Nurses Monitor Lemtrada (Alemtuzumab) Patients For Signs of Its Deadly Side Effects | 3/31/2021
- Lemtrada Can Cause Sudden Death And Many Other Health Issues | 3/8/2021
- Lemtrada May Slow the Progression of Relapse Remitting MS But with Potentially Severe Side Effects | 3/5/2021
- MS Doctors May Need To Be Reminded of Lemtrada's Deadly Side Effects | 3/1/2021
- Doctors Treating RRMS Must Discuss Lemtrada's Deadly Side Effects With Patients | 2/23/2021
- Lemtrada Can Cause An Arterial Dissection and Instant Death | 1/20/2021
- Lemtrada Toxicity May Cause Arterial Dissection Leading To Strokes | 1/13/2021
- People As Young As 20 Should Watch For Symptoms of Multiple Sclerosis | 12/30/2020
- Lemtrada Patients Could Be At Risk When Taking Covid-19 Vaccine | 12/15/2020
- Lemtrada Patients Have May Have Safer Options | 12/8/2020
- Stem Cell Rejection Could Complicate Future RRMS Treatments | 11/25/2020
- Breakthroughs In Stem Cell Transplantation Could Eliminate The Need For Lemtrada And Its Unpredictable Side Effects | 11/19/2020
- Lemtrada Patients Should Know Their Life Is In Danger By Taking Lemtrada | 11/9/2020
- Lemtrada Patients May Try Anything To Keep Multiple Sclerosis In Check | 11/4/2020
- Lemtrada Offers Hope For Those With Advanced RRMS | 10/13/2020
- Lemtrada Sometimes Works Well But Patients Were Only Recently Warned About The Dangers of The Drug | 10/6/2020
- Drugs Like Lemtrada May Benefit MS Patients Right From The Start | 9/29/2020
- Multiple Sclerosis Patients Suffer Fatigue Before Symptoms Gradually Increase | 9/23/2020
- Doctors May Have Dropped Lemtrada Over Covid-19 Fears | 9/2/2020
- Relapse Remitting Multiple Sclerosis Patients May Have a Promising New Drug | 8/25/2020
- Ofatumumab Could Replace Lemtrada For Treatment of Multiple Sclerosis | 8/8/2020
- RRMS Patients Have A Great Source of Information That Can Help Them Deal With Every Aspect of Their Disease | 8/4/2020
- New Information About COVID19 and Taking Lemtrada | 7/16/2020
- The Risks Of Lemtrada Therapy And Other DMTs | 7/9/2020
- Lemtrada Patients Face Possibility Of Living With The After-Effects of a Stroke | 7/6/2020
- A Multiple Sclerosis Doctor Explains The Ins and Outs of Lemtrada for RRMS Patients in a Series of YouTube Videos | 6/22/2020
- Lemtrada Carries Serious Side Effects That Come With The Potential Relief The Drug Offers | 6/1/2020
- Canadians Have One of the World's Highest Rates of Multiple Sclerosis | 5/28/2020
- RRMS Patients Explain Difficulty Managing The Disease During The Covid-19 Pandemic | 5/21/2020
- Relapse Remitting Multiple Sclerosis Patients Share Their Lemtrada Experiences Online | 5/12/2020
- Lemtrada May Also Cause ANCA Vasculitis | 4/27/2020
- Relapse Remitting Multiple Sclerosis Patients (RRMS) Should First Try Telephoning Their Doctors Before Risking Going To The Hospital Directly | 4/22/2020
- Experts Weigh In On Discontinuing Lemtrada Treatments During Pandemic | 4/10/2020
- Lemtrada Patients At Extreme Risk From COVID-19 | 4/8/2020
- Relapse-Remitting Multiple Sclerosis Patients Should Avoid Lemtrada (alemtuzumab) During The Covid-19 Pandemic | 3/20/2020
- Sanofi Forced To Pay $11.8 Million In Alleged Kick-Back Scheme | 3/16/2020
- Newly Diagnosed RRMS Patients Should Avoid Lemtrada and Look to Other Less Toxic Treatments | 3/11/2020
- Lemtrada Deaths Prompt Greater Scrutiny and Harsher Warnings | 2/27/2020
- Lemtrada Patients Dying At An Alarming Rate | 2/10/2020
- Lemtrada Fears May Be Overdone | 1/30/2020
- Some Patients Rave About Lemtrada's Effectiveness While Others Are Left Permanently Disabled | 1/8/2020
- One Last Lemtrada Warning for 2019 | 1/2/2020
- RRMS Patients May Try Stem Cell Therapy if Lemtrada Fails | 12/26/2019
- Lemtrada Patient's Fear of the Unknown Moderated in YouTube Testimonial Videos | 12/16/2019
- Lemtrada Side Effect Awareness Requirements | 12/11/2019
- Lemtrada is serious medication for a serious condition | 11/21/2019
- More Restrictions Placed on Multiple Sclerosis Sufferers Who Wish to Receive Lemtrada Treatment | 11/15/2019
- RRMS Patients May Look To Alternatives To Lemtrada | 11/6/2019
- Europe's Medicine Agency Increases Lemtrada Restrictions | 11/4/2019
- Understand The Pros and Cons of Lemtrada RRMS Treatments | 10/16/2019
- Lemtrada Is More Deadly Than Originally Thought | 10/10/2019
- Obesity Can Make Multiple Sclerosis Medications Less Effective | 10/2/2019
- RRMS Patients Should Consider Lemtrada's Risk of Arterial Dissection | 9/18/2019
- Multiple Sclerosis Patient Have a Difficult Decision To Make When The Disease is in its Latter Stages | 9/6/2019
- Lemtrada's Deadly Side Effects Greater Than Previously Thought | 9/2/2019
- Drug Makers Look to Mitigate Lemtrada's Life-Threatening Side Effects | 8/26/2019
- Lemtrada Relieves RRMS Symptoms Allowing Patients to Enjoy a Better Quality of Life | 8/20/2019
- Lemtrada Causes High Blood Pressure Before a Stroke Occurs | 8/6/2019
- Lemtrada Patients Report Promising Results | 8/1/2019
- The European Medicines Agency is Studying Lemtrada's Side Effects | 7/30/2019
- What To Watch For Indicating You May Have Multiple Sclerosis | 7/10/2019
- Lemtrada May Be Twice as Effective As Its Leading Competitor | 7/5/2019
- Brain Bleeding May Indicate a Lemtrada Stroke is Imminent | 6/27/2019
- Treating Multiple Sclerosis From Many Angles | 6/21/2019
- Lemtrada's Risks Exceed The Black Box Warning | 6/18/2019
- A Long-Term Study Demonstrates Lemtrada's Effectiveness and Adverse Side Effects | 6/11/2019
- A Leading Authority Finds Lemtrada Causes Brain Bleeding | 5/30/2019
- Lemtrada's Incredibly Long List of Adverse Side Effects | 5/23/2019
- The Outlook is Grim For Relapsing-Remitting Multiple Sclerosis (RRMS) Patients | 5/15/2019
- Lemtrada Forced To Update Black Box Warning To Include Chance of Stroke | 5/10/2019
- The European Medicines Agency Urges Doctors To Stop Using Lemtrada Effective Immediately | 5/4/2019
- The Pros and Cons of Lemtrada Therapy | 4/19/2019
- Europe's FDA is Reviewing Lemtrada's Stroke Side Effect | 4/15/2019
- Lemtrada is a drug that is approved for patients suffering from relapsing multiple sclerosis but can have serious and often deadly side effects. | 4/9/2019
- MS Doctors Must Weigh The Benefits of Lemtrada Versus The Drug's Stroke Risks | 4/3/2019
- Individuals Suffering From RLMS Now Have a New Drug Called Mavenclad That Can Help Alleviate Seizures | 4/1/2019
- Stroke Warning Added to Lemtrada Boxed Label | 3/28/2019
- Anti MS Drug Lemtrada Carries Multiple Lethal Side Effects | 3/25/2019
No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.